机构：[1]Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences and School of Medicine of South China University of Technology, 106 Zhongshan 2nd Road, Guangzhou 510080, China肿瘤治疗中心研究所肺肿瘤科广东省肺癌研究所广东省人民医院
Compared to chemotherapy, promising results have been obtained by blocking the PD-1 pathway using antibodies that inhibit programmed cell death protein 1 (PD-1) or programmed cell death protein ligand 1 (PD-L1). Furthermore, global researchers and doctors are exploring how to optimize this immunotherapy in 270 clinical studies. However, Chinese clinical trials of these agents remain in the early stages. We summarize the ongoing international and domestic clinical trials using PD-1 and PD-L1 inhibitors to treat lung cancer. This information can help researchers better understand the active and approved clinical trials in China, as well as the ongoing research regarding PD-1 and PD-L1 inhibitors.
基金：
Guangdong Provincial Key Laboratory of Lung Cancer Translational Medicine [2012A061400006]; National Health and Family Planning Commission of PRC [201402031]; Guangzhou Science and Technology Bureau [2014Y2-00050]
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2017]版：
大类|2 区医学
小类|2 区血液学2 区肿瘤学
最新[2023]版：
大类|1 区医学
小类|1 区血液学1 区肿瘤学
第一作者：
第一作者机构：[1]Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences and School of Medicine of South China University of Technology, 106 Zhongshan 2nd Road, Guangzhou 510080, China
通讯作者：
通讯机构：[1]Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences and School of Medicine of South China University of Technology, 106 Zhongshan 2nd Road, Guangzhou 510080, China
推荐引用方式(GB/T 7714)：
Liu Si-Yang,Wu Yi-Long.Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China[J].JOURNAL OF HEMATOLOGY & ONCOLOGY.2017,10(1):-.doi:10.1186/s13045-017-0506-z.
APA：
Liu, Si-Yang&Wu, Yi-Long.(2017).Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China.JOURNAL OF HEMATOLOGY & ONCOLOGY,10,(1)
MLA：
Liu, Si-Yang,et al."Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China".JOURNAL OF HEMATOLOGY & ONCOLOGY 10..1(2017):-
医学